POZ™- The Next Generation of Polymer Therapeutics

Serina Therapeutics, Inc. has developed a proprietary drug delivery polymer technology based upon the polymer poly(2-oxazoline), or POZ™. We are developing a pipeline of proprietary and partnered programs applying this platform to cancer, pain, refractory epilepsy, and movement disorders such as Parkinson’s disease and restless leg syndrome.

Serina Therapeutics, Inc. is a privately held biotech company located at the HudsonAlpha Institute of Biotechnology in Huntsville, Alabama.

Serina Therapeutics, Inc. was founded in 2006 by Drs. Milton Harris and Michael Bentley who developed and patented much of the polymer technology known as PEG, or PEGylation, during their work at Shearwater Polymers and Nektar Therapeutics. Despite its widespread success, PEG lacks a number of the desired features for designing an ideal polymer drug conjugate platform. Serina scientists have developed a novel proprietary portfolio based on a wholly distinct and more versatile polymer drug conjugate platform called POZ™.

The Serina Team has considerable expertise in the areas of drug delivery, research, clinical development, commercialization and licensing for a variety of novel drugs ranging from small molecules and peptides to antibody therapeutics.